SNWV SANUWAVE Health, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1417663 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.1%
TTM net income YoY128.0%
TTM EPS YoY76.9%
Revenue 3-yr CAGR29.5%
Net income 3-yr CAGR—
Margins
Gross margin76.0%
Operating margin-4.5%
Net margin6.3%
FCF margin6.3%
EBITDA margin-1.7%
Returns
ROE—
ROA7.6%
ROIC (approx.)-124.0%
Asset turnover1.20x
Leverage & solvency
Liabilities / assets91.2%
Debt / equity0.00x
Current ratio1.18x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.28x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue1.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $8.58M | $9.74M | $9.62M | $13.09M | $11.27M | $10.05M | $9.33M | $10.33M |
| Cost of revenue | $1.95M | $2.31M | $2.19M | $3.39M | $2.53M | $2.21M | $1.96M | $2.29M |
| Gross profit | $6.63M | $7.42M | $7.43M | $9.70M | $8.74M | $7.85M | $7.38M | $8.04M |
| R&D expense | $426,000 | $628,000 | $660,000 | $606,000 | $345,000 | $194,000 | $208,000 | $154,000 |
| SG&A expense | $5.13M | $4.90M | $5.25M | $6.06M | $5.19M | $4.37M | $4.84M | $3.80M |
| Operating income | -$1.07M | -$280,000 | -$1.12M | $615,000 | $903,000 | $1.44M | $601,000 | $2.01M |
| Interest expense | $276,000 | $518,000 | $546,000 | — | $1.79M | $1.94M | $1.91M | $2.52M |
| Income tax | $63,000 | $6,000 | — | $86,000 | $0 | $0 | — | — |
| Net income | -$1.42M | -$682,000 | -$1.44M | $6.11M | $9.69M | $551,000 | -$6.12M | -$13.31M |
| EBITDA | -$798,000 | -$29,000 | -$830,000 | $955,000 | $1.12M | $1.61M | $810,000 | $2.23M |
| EPS (basic) | -0.16 | -0.08 | -0.17 | — | 1.13 | 0.06 | -0.72 | — |
| EPS (diluted) | -0.16 | -0.08 | -0.17 | — | 0.39 | -0.04 | -0.72 | — |
| Weighted avg. shares (diluted) | 8.60M | 8.60M | 8.59M | — | 9.14M | 9.17M | 8.55M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.57M | $9.38M | $10.78M | $11.96M | $9.60M | $8.50M | $8.50M | $10.24M |
| Receivables | $4.96M | $5.80M | $6.00M | $5.42M | $4.62M | $3.85M | $3.87M | $3.33M |
| Inventory | $6.72M | $7.07M | $5.90M | $5.93M | $6.81M | $5.91M | $5.46M | $4.15M |
| Current assets | $19.30M | $23.20M | $23.96M | $24.63M | $22.63M | $20.17M | $18.83M | $18.40M |
| PP&E, net | $2.35M | $2.25M | $1.91M | $1.97M | $1.99M | $1.59M | $449,000 | $303,000 |
| Goodwill | $7.26M | $7.26M | $7.26M | $7.26M | $7.26M | $7.26M | $7.26M | $7.26M |
| Intangibles | $2.70M | $2.89M | $2.92M | $3.03M | $3.20M | $3.38M | $3.55M | $3.73M |
| Total assets | $32.52M | $36.60M | $37.10M | $37.34M | $35.60M | $33.05M | $30.86M | $30.12M |
| Current liabilities | $16.39M | $18.17M | $18.30M | $17.85M | $23.98M | $50.42M | $50.78M | $45.42M |
| Short-term debt | — | — | $5.75M | $5.75M | $5.75M | — | — | — |
| Long-term debt | — | — | $14.76M | $16.14M | $17.53M | — | — | — |
| Total debt | — | — | $20.51M | $21.89M | $23.28M | — | — | — |
| Total liabilities | $29.67M | $33.82M | $35.26M | $35.72M | $43.19M | $51.84M | $51.67M | $45.91M |
| Shareholders' equity | $2.85M | $2.79M | $1.84M | $1.62M | -$7.59M | -$18.80M | -$20.81M | -$15.79M |
| Net debt | — | — | $9.73M | $9.93M | $13.68M | — | — | — |
| Shares outstanding | 8.60M | 8.60M | 8.59M | 8.59M | 8.58M | 8.57M | 8.55M | 8.54M |
| Cash flow statement | ||||||||
| Operating cash flow | -$851,000 | $425,000 | $397,000 | $3.32M | $1.08M | $993,000 | -$1.52M | $741,000 |
| Capital expenditure | $236,000 | $334,000 | $23,000 | $96,000 | $525,000 | $1.16M | $162,000 | $236,000 |
| Free cash flow | -$1.09M | $91,000 | $374,000 | $3.22M | $556,000 | -$166,000 | -$1.68M | $505,000 |
| Investing cash flow | -$205,000 | -$448,000 | -$158,000 | $279,000 | $4.47M | -$1.16M | -$162,000 | -$236,000 |
| Financing cash flow | -$1.75M | -$1.38M | -$1.42M | -$1.24M | -$4.45M | $161,000 | -$57,000 | $6.47M |
| Depreciation & amortization | $274,000 | $251,000 | $294,000 | $340,000 | $222,000 | $174,000 | $209,000 | $218,000 |
| Stock-based compensation | $1.48M | $1.57M | $1.61M | $1.34M | $1.40M | $1.13M | $975,000 | $1.51M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.